Clinical Convergence®: Achieving Success in RA Assessment and Management
Rheumatology
Curriculum:
Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes
Achieving Success in RA Assessment and Management: A Learner Pathway to Improve Patient Outcomes
Credits:
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 26, 2017
December 26, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Rheumatologists
Relevant Terms:
Rheumatoid Arthritis
Martin Jan Bergman, MD, FACR, FACP, FCPP
Martin Jan Bergman, MD, FACR, FACP, FCPP
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA
Bio
Clinical Associate Professor of Medicine
Drexel University School of Medicine
Philadelphia, PA
Taylor Hospital
Ridley Park, PA
Martin Jan Bergman, MD, FACR, FACP, FCPP, is a clinical associate professor of medicine at the Drexel University School of Medicine in Philadelphia, PA. He is also a full-time clinical rheumatologist in a private practice setting, with nearly 30 years of clinical experience.
In addition to issues affecting the running of a successful clinical practice, Dr Bergman is interested in issues facing practicing rheumatologists on a daily basis. With collaborators, Dr Bergman has played a pivotal role in the development of patient management tools, particularly the Routine Assessment of Patient Index Data 3 (RAPID3). This disease measurement tool is now an outcomes measure accepted by the American College of Rheumatology and used worldwide.
Dr Bergman is a recognized leader in the field of clinical and patient reported outcomes, and has spoken both nationally and internationally on this and other topics. For his work, he has received the Joseph L. Hollander Award for Excellence and Achievement in Rheumatology by the Southeast Pennsylvania Arthritis Foundation and has been elected as a fellow of the College of Physicians of Philadelphia.
Sergio Schwartzman, MD
Sergio Schwartzman, MD
Franchellie M. Cadwell Associate Professor of Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY
Bio
Sergio Schwartzman, MD, is the Franchellie M. Cadwell associate professor of clinical medicine at Cornell Weill Medical College, and associate attending physician at New York Presbyterian Hospital and the Hospital for Special Surgery in New York, NY. Dr Schwartzman earned his medical degree at Mount Sinai School of Medicine in New York, NY. He completed his internship and residency in internal medicine at Long Island Jewish Hillside Medical Center in New Hyde Park, NY. His fellowship was conducted in the Department of Rheumatic Diseases at the New York Hospital and the Hospital for Special Surgery.
Dr Schwartzman has authored or coauthored over 70 articles, abstracts, books, and book chapters concerning rheumatoid arthritis, lupus, autoimmune ophthalmic disease, and related topics. He is a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network, the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Dr Schwartzman is the recipient of The Fellows Award presented by the Northeast Regional American Rheumatism Association and The Franchellie M. Cadwell Chair. He has served as an Ad Hoc Journal Reviewer for: Arthritis & Rheumatism, Emerging Infectious Diseases, Journal of Rheumatology, The Musculoskeletal Journal of Hospital for Special Surgery, Seminars in Arthritis and Rheumatism, Arthritis Research & Therapy, Medscape Rheumatology Editorial Advisory Board Arthritis Care and Research, WebMD Rheumatology Editorial Board, and UpToDate. Additionally, he was a member of the following ACR committees: 2010 ACR Abstract Selection Committee Spondyloarthropathies and Psoriatic Arthritis, 2012 ACR Abstract Selection Committee Rheumatoid Arthritis, and 2013 and 2014 ACR Abstract Selection Committee Rheumatoid Arthritis. He has lectured frequently at the ACR Meet the Professor Sessions on difficult-to-treat RA, and autoimmune ophthalmic diseases.
Dr Schwartzman is on the National Psoriasis Foundation Board and The Scientific Advisory Board of Crescendo Biosciences, and is the research director for Discus Analytics. His current research interests spans RA outcomes and therapy, psoriatic arthritis therapy, defining and treating autoimmune diseases of the eye including uveitis, vasculitis, scleritis, and autoimmune orbital inflammatory disease, and the spondyloarthritis group of diseases including understanding the microbiome in this group of illnesses.
Dr Schwartzman has authored or coauthored over 70 articles, abstracts, books, and book chapters concerning rheumatoid arthritis, lupus, autoimmune ophthalmic disease, and related topics. He is a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network, the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Dr Schwartzman is the recipient of The Fellows Award presented by the Northeast Regional American Rheumatism Association and The Franchellie M. Cadwell Chair. He has served as an Ad Hoc Journal Reviewer for: Arthritis & Rheumatism, Emerging Infectious Diseases, Journal of Rheumatology, The Musculoskeletal Journal of Hospital for Special Surgery, Seminars in Arthritis and Rheumatism, Arthritis Research & Therapy, Medscape Rheumatology Editorial Advisory Board Arthritis Care and Research, WebMD Rheumatology Editorial Board, and UpToDate. Additionally, he was a member of the following ACR committees: 2010 ACR Abstract Selection Committee Spondyloarthropathies and Psoriatic Arthritis, 2012 ACR Abstract Selection Committee Rheumatoid Arthritis, and 2013 and 2014 ACR Abstract Selection Committee Rheumatoid Arthritis. He has lectured frequently at the ACR Meet the Professor Sessions on difficult-to-treat RA, and autoimmune ophthalmic diseases.
Dr Schwartzman is on the National Psoriasis Foundation Board and The Scientific Advisory Board of Crescendo Biosciences, and is the research director for Discus Analytics. His current research interests spans RA outcomes and therapy, psoriatic arthritis therapy, defining and treating autoimmune diseases of the eye including uveitis, vasculitis, scleritis, and autoimmune orbital inflammatory disease, and the spondyloarthritis group of diseases including understanding the microbiome in this group of illnesses.
| 1. | Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach | 2. | Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA |
| 3. | Develop individualized treatment plans for patients with RA that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDS) based on safety and efficacy data | 4. | Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options |
| 5. | Integrate shared decision making and other patient education strategies for patients with RA |
| 1. | Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach |
| 2. | Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA |
| 3. | Develop individualized treatment plans for patients with RA that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDS) based on safety and efficacy data |
| 4. | Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options |
| 5. | Integrate shared decision making and other patient education strategies for patients with RA |
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour. Pharmacotherapy contact hours for Advance Practice Registered Nurses is 0.5
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, and Sanofi (Advisory Boards); AbbVie, Celgene, Novartis, and Sanofi (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); Johnson & Johnson, Merck, and Pfizer (Ownership Interest).
- Sergio Schwartzman, MD, has affiliations with AbbVie, Crescendo, Genentech, Hospira, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB (Speaker’s Bureau); Amgen, Gilead, Medtronic, and Pfizer (Ownership Interest); AbbVie, Crescendo, Epirus, Genentech, Hospira, Janssen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi (Consulting Fees); and Crescendo (Advisory Board).
RMEI Medical Education, LLC
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
- Jessica Hatch has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers: Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1 hour
Media: Internet
FEE INFORMATION
There is no fee for this educational activity.
STATEMENT OF SUPPORT
Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 1 AMA PRA Category 1 Credit(s)™, 1 ANCC contact hour, and 0.5 APRN contact hour. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
